Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
14.74
+0.41 (2.86%)
At close: Jun 26, 2025, 4:00 PM
14.65
-0.09 (-0.61%)
Pre-market: Jun 27, 2025, 4:57 AM EDT
Biohaven Employees
Biohaven had 256 employees as of December 31, 2024. The number of employees increased by 17 or 7.11% compared to the previous year.
Employees
256
Change (1Y)
17
Growth (1Y)
7.11%
Revenue / Employee
n/a
Profits / Employee
-$3,471,074
Market Cap
1.51B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 256 | 17 | 7.11% |
| Dec 31, 2023 | 239 | 37 | 18.32% |
| Dec 31, 2022 | 202 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
BHVN News
- 16 days ago - Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development - GlobeNewsWire
- 4 weeks ago - Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor - PRNewsWire
- 4 weeks ago - Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN) - PRNewsWire
- 4 weeks ago - Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors - PRNewsWire
- 6 weeks ago - Why Is Biohaven Stock Falling On Thursday? - Benzinga
- 6 weeks ago - FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia - PRNewsWire
- 6 weeks ago - Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments - PRNewsWire
- 7 weeks ago - Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict - Seeking Alpha